Literature DB >> 3817866

Purification of eosinophils from normal human blood, preparation of eosinoplasts and characterization of their functional response to various stimuli.

M Yazdanbakhsh, C M Eckmann, M De Boer, D Roos.   

Abstract

Eosinophils from the blood of normal individuals were purified by centrifugation over discontinuous Percoll gradients. Eosinophil suspensions were obtained with a mean purity of 96% and a mean recovery of 64% (n = 19). When incubated with phorbol-myristate acetate, eosinophils consumed twice as much oxygen as did neutrophils from the same donors. With serum-treated zymosan, 70% and 100% of the maximal oxidative response (i.e. the response to phorbol-myristate acetate) was obtained with eosinophils and neutrophils, respectively. The calcium ionophore A23187 is a weak stimulus that triggered only 2.5% of the eosinophil and 10% of the neutrophil oxidative capacity. The response of both cell types to formyl-methionyl-leucyl-phenylalanine (fMLP) was rapid, with a maximum after 3 min. The magnitude of this eosinophil reaction was half that of neutrophils. Although the activities of the granule enzymes beta-glucuronidase and arylsulphatase were 2.5 and 6 times higher in eosinophils than in neutrophils, respectively, the exocytosis of these enzymes in response to various stimuli was lower in eosinophils. The high yield of eosinophils from our separation method enabled us to prepare eosinoplasts by centrifugation of eosinophils over discontinuous Ficoll gradients that contained cytochalasin B. Eosinoplasts are plasma membrane vesicles derived from eosinophils, filled with cytoplasm but devoid of granules and nucleus. The eosinoplasts contained 30% of the cytoplasm and plasma membrane present in intact eosinophils. Eosinoplasts still possessed a functionally intact oxidase enzyme that could be stimulated with various stimuli. Therefore, eosinoplasts may provide a valuable tool to study separately the role of the oxidase products and that of the granule contents in eosinophil functions.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3817866      PMCID: PMC1453348     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  39 in total

1.  Eosinophils as mediators of antibody-dependent damage to schistosomula.

Authors:  A E Butterworth; R F Sturrock; V Houba; A A Mahmoud; A Sher; P H Rees
Journal:  Nature       Date:  1975-08-28       Impact factor: 49.962

2.  Effect of cytochalasin B on the oxidative metabolism of human peripheral blood granulocytes.

Authors:  D Roos; J W Homan-Müller; R S Weening
Journal:  Biochem Biophys Res Commun       Date:  1976-01-12       Impact factor: 3.575

3.  Studies on blood eosinophils. I. Patients with a transient eosinophilia.

Authors:  P C Tai; C J Spry
Journal:  Clin Exp Immunol       Date:  1976-06       Impact factor: 4.330

4.  Oxygen consumption of phagocytizing cells in human leukocyte and granulocyte preparations: a comparative study.

Authors:  R S Weening; D Roos; J A Loos
Journal:  J Lab Clin Med       Date:  1974-04

5.  Eosinophil cell separation from human peripheral blood.

Authors:  R P Day
Journal:  Immunology       Date:  1970-06       Impact factor: 7.397

6.  Changes in the carbohydrate metabolism of mitogenically stimulated human peripheral lymphocytes. I. Stimulation by phytohaemagglutinin.

Authors:  D Roos; J A Loos
Journal:  Biochim Biophys Acta       Date:  1970-12-29

7.  Metabolic and bactericidal activities of human eosinophils.

Authors:  R L Baehner; R B Johnston
Journal:  Br J Haematol       Date:  1971-03       Impact factor: 6.998

8.  Complement and immunoglobulins stimulate superoxide production by human leukocytes independently of phagocytosis.

Authors:  I M Goldstein; D Roos; H B Kaplan; G Weissmann
Journal:  J Clin Invest       Date:  1975-11       Impact factor: 14.808

9.  Isolation and partial characterization of human eosinophil granules. Comparison to neutrophils.

Authors:  B C West; N A Gelb; A S Rosenthal
Journal:  Am J Pathol       Date:  1975-12       Impact factor: 4.307

10.  Histaminase release from human eosinophils.

Authors:  R S Zeiger; H R Colten
Journal:  J Immunol       Date:  1977-02       Impact factor: 5.422

View more
  8 in total

1.  Phospholipase D-derived phosphatidic acid is involved in the activation of the CD11b/CD18 integrin in human eosinophils.

Authors:  A T Tool; M Blom; D Roos; A J Verhoeven
Journal:  Biochem J       Date:  1999-05-15       Impact factor: 3.857

2.  Granulocyte-macrophage colony-stimulating factor and interleukin-3 induce surface expression of interleukin-2 receptor p55-chain and CD4 by human eosinophils.

Authors:  D Riedel; A Lindemann; M Brach; R Mertelsmann; F Herrmann
Journal:  Immunology       Date:  1990-06       Impact factor: 7.397

Review 3.  Voltage-gated proton channels: molecular biology, physiology, and pathophysiology of the H(V) family.

Authors:  Thomas E DeCoursey
Journal:  Physiol Rev       Date:  2013-04       Impact factor: 37.312

4.  Mature human eosinophils have the capacity to express HLA-DR.

Authors:  D R Lucey; A Nicholson-Weller; P F Weller
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

5.  Immunocytochemical localization of arachidonate 15-lipoxygenase in erythrocytes, leukocytes, and airway cells.

Authors:  J A Nadel; D J Conrad; I F Ueki; A Schuster; E Sigal
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

Review 6.  The intimate and controversial relationship between voltage-gated proton channels and the phagocyte NADPH oxidase.

Authors:  Thomas E DeCoursey
Journal:  Immunol Rev       Date:  2016-09       Impact factor: 12.988

7.  FMLP is a potent activator of guinea-pig eosinophils but its activity is dependent on the prior overnight in vitro culture of the cells (facilitation).

Authors:  M K Bach; J R Brashler
Journal:  Immunology       Date:  1992-04       Impact factor: 7.397

8.  Human eosinophils express CD4 protein and bind human immunodeficiency virus 1 gp120.

Authors:  D R Lucey; D I Dorsky; A Nicholson-Weller; P F Weller
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.